Drug Trial News

RSS

Mount Sinai to initiate immunological therapy trial against chronic pulmonary sarcoidosis

Patients are currently being enrolled in the first clinical trial to investigate the efficacy of immunological therapy for chronic pulmonary sarcoidosis. The trial is being conducted by researchers at the Icahn School of Medicine at Mount Sinai.

31 Jan 2013

No proof of added benefit from aclidinium bromide in adults with COPD

The drug aclidinium bromide has been approved since October 2012 for widening the narrowed airways of adults with chronic-obstructive pulmonary disease (COPD). The German Institute for Quality and Efficiency in Health Care (IQWiG) has now examined the added benefit of the drug pursuant to the "Act on the Reform of the Market for Medicinal Products" (AMNOG).

31 Jan 2013

No added benefit from perampanel in patients with epileptic fits

The drug perampanel has been approved since July 2012 as adjunctive therapy for adults and children aged 12 years and older with epileptic fits (seizures).

30 Jan 2013

Dilaforette receives approval to initiate sevuparin Phase II malaria study in India

Dilaforette, a Karolinska Development portfolio company, today announces that the company has approval from the regulatory authority in India to start a Phase II study with sevuparin in patients with moderate to severe malaria.

30 Jan 2013

Acceleron commences ACE-536 phase 2 study in myelodysplastic syndromes

Acceleron Pharma, Inc., a biopharmaceutical company developing protein therapeutics for cancer and orphan diseases, today announced the initiation of a phase 2 study of its investigational protein therapeutic, ACE-536, to treat anemia in patients with myelodysplastic syndromes (MDS).

30 Jan 2013

OncoPep commences PVX-410 Phase 1/2a trial in smoldering multiple myeloma

OncoPep, Inc. today announced that the Company has initiated a Phase 1/2a clinical trial evaluating PVX-410, a multi-peptide therapeutic cancer vaccine, in patients with smoldering multiple myeloma, an asymptomatic precursor of multiple myeloma, which is an incurable cancer of the plasma cells.

30 Jan 2013

FDA allows IND application for ImmunoCellular’s ICT-140 to treat ovarian cancer

ImmunoCellular Therapeutics, Ltd. announced that the US Food and Drug Administration (FDA) has allowed the investigational new drug (IND) application for ICT-140, paving the way for conducting a clinical trial.

30 Jan 2013

Botulinum toxin A does not promote weight loss in obese patients

Despite conflicting data in support of the practice, some overweight Americans looking for an easy fix have turned to gastric botox injections to help them lose weight. This month in Clinical Gastroenterology and Hepatology, the official clinical practice journal of the American Gastroenterological Association, researchers from the Mayo Clinic publish a definitive study finding that Botox doesn't promote weight loss.

29 Jan 2013

Bone Medical announces initial findings from BN006 proof of concept RA study

Bone Medical Ltd, a biopharmaceutical company focused on the development of new medicines for musculoskeletal diseases, today announced initial findings from a proof of concept study of BN006, a treatment that it is developing for Rheumatoid Arthritis (RA) based on its Mozaic™ peptide discovery technology.

29 Jan 2013

Janssen, Medivir and Idenix partner for clinical development of HCV combination therapy

Medivir AB today announced a non-exclusive collaboration between Janssen Pharmaceuticals Inc. (Janssen) and Idenix Pharmaceuticals for the clinical development of an all-oral (interferon-free) direct-acting antiviral (DAA) hepatitis C (HCV) combination therapy.

29 Jan 2013

Millennium, Seattle Genetics commence ADCETRIS plus chemotherapy phase III trial in MTCL

Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited (TSE:4502), today announced the initiation of a global phase III clinical trial evaluating ADCETRIS (brentuximab vedotin) in combination with chemotherapy for the treatment of newly diagnosed CD30-positive mature T-cell lymphoma (MTCL) patients, including patients with systemic anaplastic large cell lymphoma (sALCL) and other types of peripheral T-cell lymphomas.

28 Jan 2013

Positive top-line results from Biogen Idec’s peginterferon beta-1a Phase 3 trial on RRMS

Today Biogen Idec released the primary efficacy analysis and safety data from its Phase 3 pivotal clinical trial, ADVANCE.

28 Jan 2013

Gilead commences first of two tenofovir alafenamide Phase 3 trials in HIV

Gilead Sciences, Inc. today announced the initiation of the first of two Phase 3 clinical trials (Study 104) evaluating a single tablet regimen containing tenofovir alafenamide (TAF) for the treatment of HIV-1 infection in treatment-naïve adults.

28 Jan 2013

Results from Amgen’s Neulasta plus bevacizumab Phase 3 trial on colorectal cancer

Amgen announced today results from Pegfilgrastim and Anti-VEGF Evaluation Study (PAVES), a Phase 3 trial which evaluated Neulasta (pegfilgrastim) in 845 patients receiving FOLFOX or FOLFIRI and bevacizumab for the first-line treatment of locally-advanced or metastatic colorectal cancer.

28 Jan 2013

Interim results from Seattle Genetics’ ASG-5ME phase I trial on metastatic PDA

Seattle Genetics, Inc. today presented interim results from a phase I clinical trial evaluating ASG-5ME for the treatment of metastatic pancreatic ductal adenocarcinoma (PDA) at the American Society of Clinical Oncology (ASCO) 2013 Gastrointestinal Cancers Symposium being held January 24-26, 2013 in San Francisco, CA.

28 Jan 2013

Researchers study innovative stem cell drug for treating localized cartilage damage

Rush University Medical Center is conducting the nation's first clinical study of an innovative stem cell drug, Cartistem, to repair knee cartilage damaged by aging, trauma or degenerative diseases such as osteoarthritis.

25 Jan 2013

New hope for lupus patients

A clinical trial with 149 patients suffering from the very disabling autoimmune disease systemic lupus erythematosus, has shown the effectiveness of a synthetic peptide developed by a team of researchers led by CNRS biologist Slyviane Muller at the Institut de Biologie Moleculaire (IBMC) in Strasbourg, France.

25 Jan 2013

Neuromuscular blockade (NMB) reversal

General anesthesia is made up of three components: hypnotic medicines, to induce sleep; analgesics, or medicines to inhibit pain; and NMB agents that induce muscle relaxation. Anesthesiology professionals use NMB to relax a patient’s muscles and prevent involuntary movement that could impact surgery.

24 Jan 2013

Clinical trial to evaluate cyclodextrin against Niemann-Pick disease type C1

A clinical trial to evaluate a drug candidate called cyclodextrin as a possible treatment for Niemann-Pick disease type C1 (NPC), a rare and fatal genetic disease, will start today, researchers announced.

24 Jan 2013

Tofacitinib improves disease activity and inhibits progression of joint damage in RA patients

A Phase 3 clinical trial demonstrates that tofacitinib improves disease activity and inhibits progression of joint damage in rheumatoid arthritis (RA) patients who did not respond to methotrexate (MTX).

24 Jan 2013

Drug Trial News

Mount Sinai to initiate immunological therapy trial against chronic pulmonary sarcoidosis

No proof of added benefit from aclidinium bromide in adults with COPD

No added benefit from perampanel in patients with epileptic fits

Dilaforette receives approval to initiate sevuparin Phase II malaria study in India

Acceleron commences ACE-536 phase 2 study in myelodysplastic syndromes

OncoPep commences PVX-410 Phase 1/2a trial in smoldering multiple myeloma

FDA allows IND application for ImmunoCellular’s ICT-140 to treat ovarian cancer

Botulinum toxin A does not promote weight loss in obese patients

Bone Medical announces initial findings from BN006 proof of concept RA study

Janssen, Medivir and Idenix partner for clinical development of HCV combination therapy

Millennium, Seattle Genetics commence ADCETRIS plus chemotherapy phase III trial in MTCL

Positive top-line results from Biogen Idec’s peginterferon beta-1a Phase 3 trial on RRMS

Gilead commences first of two tenofovir alafenamide Phase 3 trials in HIV

Results from Amgen’s Neulasta plus bevacizumab Phase 3 trial on colorectal cancer

Interim results from Seattle Genetics’ ASG-5ME phase I trial on metastatic PDA

Researchers study innovative stem cell drug for treating localized cartilage damage

New hope for lupus patients

Neuromuscular blockade (NMB) reversal

Clinical trial to evaluate cyclodextrin against Niemann-Pick disease type C1

Tofacitinib improves disease activity and inhibits progression of joint damage in RA patients

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News